Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

MI Care

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 3
Lead investments 1
Exits 2
Key employees Soon

Areas of investment

  • Pharmaceutical
  • Medical
  • Health Diagnostics
  • Therapeutics
  • Biotechnology
Summary

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2017. The higher amount of exits for fund were in 2017.

Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Advicenne. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 5-6 partakers. The meaningful sponsors for the fund in investment in the same round are Sofipaca, Sham Innovation Santu00e9, Quest for Growth.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of MI Care:
Typical Co-investors
MI Care is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after MI Care:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Apsara Investments Central, Central Region, Singapore
Business Builders California, Cupertino, United States
East Wings Finland, Helsinki, Southern Finland
ECentury Capital Partners Mclean, United States, Virginia
Fundamental Films China, Shanghai
Godavari Biorefineries India, Maharashtra, Mumbai
Iratel Ventures England, London, United Kingdom
Leap Wireless California, San Diego, United States
Litigit -
Moscar Capital England, London, United Kingdom
New World Angels Boca Raton, Florida, United States
RLG Capital Park City, United States, Utah
Rotunda Capital Partners Bethesda, Maryland, United States
RPR Venture -
Sabby Capital New Jersey, United States, Upper Saddle River
Sequoia Heritage California, Menlo Park, United States
Silk Road Huachuang Beijing, Beijing, China
Thuasne -
Yingxue Ziben China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

HalioDx

Health Diagnostics
Medical
Pharmaceutical
$21M17 Jan 2018 Marseille, Provence-Alpes-Côte d'Azur, France

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MI Care?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 3
Average round size 19M
Peak activity year 2017
Lead investments 1
Exits 2
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

HalioDx

Health Diagnostics
Medical
Pharmaceutical
$21M17 Jan 2018 Marseille, Provence-Alpes-Côte d'Azur, France
Crunchbase icon

Content report

The following text will be sent to our editors: